Green Sun’s dynamic brace applies continuous corrective pressure to the spine of adolescent patients with scoliosis.
Funds from the Employment Achievement Award from the Triumph Foundation will offset clinical trial costs.
The company has developed a better fetal monitor to improve outcomes for mothers and babies during childbirth.
The new standard of care will reduce anxiety and risks for hospitalized patients.
Arterys unveiled the MICA platform in Chicago at the Radiological Society of North America annual meeting.
Arterys will expand its web-based AI platform, launch several products, and accelerate its cardiac offering.
Catalia can roll out their platform to patients and expand their AI platform into new disease states.
2017 Rosenman Innovator Encellin and founder and CEO Crystal Nyitray featured recently on the nation's premier public radio forum.
Scientists in California think they may have found a way to transplant insulin-producing cells into diabetic patients who lack those cells — and protect the little insulin-producers from immune rejection. Their system, one of several promising approaches under development, hasn't yet been tested in people. But if it works, it could make living with diabetes much less of a burden.
For now, patients with Type-1 diabetes have to regularly test their blood sugar levels, and inject themselves with insulin when it's needed.
Some researchers are developing machines to automate that process.
But Crystal Nyitray, founder and CEO of the biotechnology startup Encellin, in San Francisco, didn't want to use a machine to treat diabetes. As a graduate student in bioengineering at the University of California, San Francisco a few years ago, Nyitray wanted to try something different: living cells.
2017 Rosenman Innovator Green Sun Medical was awarded the top cash prize of $50,000 during the FDA-sponsored pediatric medical device competition at the Fifth Annual Pediatric Device Innovation Symposium in San Jose, Calif. organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.
Green Sun Medical is developing a dynamic scoliosis brace that will allow physicians to remotely monitor the performance on the patients.
“We are honored to have our scoliosis brace recognized with these other pediatric device innovations,” said Jamie Haggard, CEO of Green Sun Medical. He also said that current treatments include braces developed over 40 years ago and spinal fusion surgeries.
Congratulations to Rosenman Fellow Bill Malecki, co-founder, COO, and CTO of Channel Medsystems!
EMERYVILLE, Calif., Aug. 23, 2017 /PRNewswire/ -- Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific.
Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding. Cerene allows women who are finished with childbearing to receive treatment in their gynecologist's office, a more comfortable and less-expensive setting of care than a hospital or surgery center. The Company plans to use this funding to support initiatives leading up to anticipated FDA approval as well as initial preparation for commercial launch.
We're proud to announce the 2017 cohort of Rosenman Innovators, some of the most promising medtech startups in the San Francisco Bay Area: AesculaTech, Blumio, DeviceFarm, Gravitas Medical, Green Sun Medical, Intelligent Implants, Raydiant Oximetry, Siris Medical, Zenflow, and Zeto.
The Innovators are a group of dynamic startups with the potential to grow and rapidly commercialize medical device technologies that will deliver significant benefits to doctors and patients. A panel of judges including Rosenman Fellows chose the Innovators from more than 80 applicants.
At the Rosenman Symposium, Wednesday, June 21, at UCSF Mission Bay, the Innovators gave lightning pitches to a packed Byers Auditorium. Earlier in the day, in an extended session, they had presented to a private group of industry partners and accredited investors.
The Innovators represent a wide range of technologies, include implants, orthotics, fetal monitoring, and machine-learning software for cancer diagnosis.
Innovator founders received professional coaching on business model and presentation. At the culminating event, the Innovators were introduced to industry partners who could join forces--share resources and expertise--on technologies of mutual interest--and investors (in some cases, venture arms of industry partners) who could provide mentorship and further valuable introductions in addition to funding for operations.
In-kind services for the 2017 Rosenman Innovators were provided by BioSurg (support with animal protocol and animal facility time); IO LifeScience (design & engineering consultation, prototyping); NextFlex (prototyping & pilot manufacturing, flexible electronics); Propel(x) (exposure to early-stage investors); ProtoQuick (design consultation, CNC, injection molding); and Whipsaw (design & engineering consultation).
Congratulations to Velano on a truly impressive early round of funding to advance its technology.
Velano Vascular announced today that it has secured $17 million in financing, which will be used to scale and commercialize a family of vascular access technologies, including the PIVO™ needle-free device that seeks to improve the overall blood draw experience for patients and practitioners.
A publicly traded healthcare company and a global supplier join existing investors First Round Capital, Griffin Hospital, Kapor Capital, Safeguard Scientifics, Sutter Health, The Children’s Hospital of Philadelphia, White Owl Capital, and a number of health-industry veterans in supporting Velano Vascular’s mission to reduce the pain, risk, and inefficiencies of vascular access and blood collection practices.
“This level of investment is a tremendous validation of our team’s effort to establish a true, more compassionate standard of care,” said Velano Vascular CEO Eric M. Stone. “Tens of thousands of PIVO draws across multiple health systems in the U.S. and overseas reflect that there is a better, more efficient way to draw blood. This funding will allow us to meet the growing commercial demand and to touch millions of lives in the years ahead.”
Hospital inpatient blood draws are one of the world’s most common invasive medical procedures, with an estimated 1 billion occurring globally every year and more than 400 million in U.S. hospitals alone. Hospitals use of needles and central line access for blood collection can create unnecessary pain and anxiety for patients, the potential for patient harm, and the possibility of practitioner injury. These challenges are further complicated by the immense inefficiencies associated with collecting laboratory samples in the rising population of the estimated 30% of DVA (Difficult Venous Access) patients, due in part to the increasing prevalence of obesity, aging and chronic illness.
“Our ongoing investments in Velano are driven by our belief that this revolutionary technology addresses a significant unmet need supported by mounting market demand,” said David Mars, Managing Director of early Velano investor White Owl Capital. “It also provides a rare opportunity to work with an inspiring team of patient-centered innovators and a company that will positively impact millions of patients and caregivers around the world.”
PIVO is a single-use, disposable device that enables high quality blood samples via indwelling peripheral IV lines, supporting hospitals’ reduced reliance on repeat needle sticks and central line access for blood collection. PIVO seeks to provide a more compassionate care experience for patients, a safer environment for practitioners, and a more financially responsible alternative for health systems.
Velano recently received FDA clearance for their PIVO Next Gen device!
The FDA cleared Velano Vascular’s second iteration of its needle-free blood draw device, which attaches to the peripheral IV line that most hospital patients already have, cutting down on repeated needle sticks that are the norm for blood collection.
A peripheral IV, used to deliver fluids, medication or nutrients, may be used to draw blood, but only upon insertion. The single-use, disposable PIVO device attaches to the IV line and advances a small, flexible catheter through it. From here, the device aspirates blood samples without needing to stick the patient multiple times, said Velano Vascular CEO Eric Stone previously.
While the device makes blood draws more comfortable for the patient, it also reduces practitioners’ exposure to needles, Stone said. In the long term, the PIVO device could potentially standardize blood collection across hospitals and health systems.